Wegovy + Bimagrumab: A Dual Breakthrough in Fat Loss and Muscle Preservation At the ADA meeting, Eli Lilly and Novo Nordisk unveiled new data from the Phase 2b BELIEVE trial, evaluating the combination of Wegovy (semaglutide) with Bimagrumab for the treatment of obesity
[1] The most frequently reported gastrointestinal side effects include: Nausea (very common, affecting more than 1 in 10 patients) Diarrhoea (very common, affecting more than 1 in 10 patients) Vomiting (common to very common, depending on dose) Decreased appetite (very common) Constipation Abdominal pain or discomfort Dyspepsia (indigestion) Belching , which may occasionally have a sulphurous odour These symptoms typically occur because GLP-1 receptor agonists slow gastric emptyingthe rate at which food leaves the stomachand alter gastrointestinal motility
Final pricing will depend on regulatory approval, manufacturing scale, and market launch strategy
AIDS 8: 655-660.CrossRefGoogle ScholarPubMed DI GIACOMO, C., LATTERI, F., FICHERA, C., SORRENTI, V., CAMPISI, A., CASTORINA, C., RUSSO, A., PINTURO, R